Long-term immune-related adverse events under PD-1 inhibitors: a multicenter prospective cohort study (MELBASE).
Charlée Nardin(CHU Dijon Bourgogne), F. Aubin(Centre Hospitalier Universitaire de Besançon), M.‐T. Leccia(Centre Hospitalier Universitaire de Grenoble), O. Dereure(Beth Israel Deaconess Medical Center), Wendy Lefevre(Inserm), Célèste Lebbé(Inserm), S. Dalac‐Rat(Centre Hospitalier du Mans), F. Granel‐Brocard(Centre Hospitalier Régional et Universitaire de Nancy), Henri Montaudié(Hôpital l'Archet), F. Brunet‐Possenti(Inserm), Délphine Legoupil(Centre Hospitalier Régional Universitaire de Brest), Caroline Dutriaux(Centre Hospitalier Universitaire de Bordeaux), Clara Allayous(Inserm), Stéphane Dalle(Hospices Civils de Lyon), Myrtille Le-Bouar(Hospices Civils de Lyon), Laurent Mortier, Julie De Quatrebarbes(Centre Hospitalier Annecy Genevois), J. Charles(Apple (Israel)), Brigitte Dréno(Nantes Université)
Cited by 3
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma
|New England Journal of Medicine|2014|2k
Adjuvant Dabrafenib plus Trametinib in Stage III<i>BRAF</i>-Mutated Melanoma
|New England Journal of Medicine|2017|1.5k
Randomized Phase III Study of Temozolomide Versus Dacarbazine in the Treatment of Patients With Advanced Metastatic Malignant Melanoma
|Journal of Clinical Oncology|2000|1.3k